Differential drug responses of circulating tumor cells within patient blood

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 28-35

  Hughes, Andrew D ^a   Marshall, Jocelyn R ^a   Keller, Eric ^b,c   Powderly, John D ^b,c   Greene, Bryan T ^b,c   King, Michael R ^a  

^a School of Operations Research and Industrial Engineering   (United States)

^b BioCytics Inc   (United States)

^c PLLC   (United States)

Author keywords

Chemotherapy; Circulating tumor cell; Drug resistance; Personalized medicine

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; MITOXANTRONE;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL LINE; CELL COUNT; CELL ISOLATION; CELL VIABILITY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SPIKE;

CHEMOTHERAPY; CIRCULATING TUMOR CELL; DRUG RESISTANCE; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING;

EID: 84906058293     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.026     Document Type: Article

References (36)

1. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
2. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 2010, 362:2380-2388.
3. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205:275-292.
4. Samson D.J., Seidenfeld J., Ziegler K., Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 2004, 22:3618-3630.
5. Gonzalez-Garcia I., Sole R.V., Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc. Natl. Acad. Sci. USA 2002, 99:13085-13089.
6. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
7. Sun Y., Campisi J., Higano C., Beer T.M., Porter P., Coleman I., True L., Nelson P.S. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 2012, 18:1359-1368.
8. Hughes A.D., King M.R. Nanobiotechnology for the capture and manipulation of circulating tumor cells. Wires Nanomed. Nanobiotechnol. 2012, 4:291-309.
9. De Giorgi U., Mego M., Rohren E.M., Liu P., Handy B.C., Reuben J.M., Macapinlac H.A., Hortobagyi G.N., Cristofanilli M., Ueno N.T. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J. Nucl. Med. 2010, 51:1213-1218.
10. Maheswaran S., Haber D.A. Circulating tumor cells: a window into cancer biology and metastasis. Curr. Opin. Genet. Dev. 2010, 20:96-99.
11. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
12. Miller M.C., Doyle G.V., Terstappen L.W. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 2010:617421.
13. Davnall F., Yip C.S., Ljungqvist G., Selmi M., Ng F., Sanghera B., Ganeshan B., Miles K.A., Cook G.J., Goh V. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. Insights Imaging 2012, 3:573-589.
14. Wittekind C., Neid M. Cancer invasion and metastasis. Oncology 2005, 69(Suppl 1):14-16.
15. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
16. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M., Concannon K.F., Donaldson M.C., Sequist L.V., Brachtel E., Sgroi D., Baselga J., Ramaswamy S., Toner M., Haber D.A., Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
17. Miyamoto D.T., Lee R.J., Stott S.L., Ting D.T., Wittner B.S., Ulman M., Smas M.E., Lord J.B., Brannigan B.W., Trautwein J., Bander N.H., Wu C.L., Sequist L.V., Smith M.R., Ramaswamy S., Toner M., Maheswaran S., Haber D.A. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012, 2:995-1003.
18. Hughes A.D., Mattison J., Western L.T., Powderly J.D., Greene B.T., King M.R. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood. Clin. Chem. 2012, 58:846-853.
19. Hughes A.D., Mattison J., Powderly J.D., Greene B.T., King M.R. Rapid isolation of viable circulating tumor cells from patient blood samples. J. Vis. Exp. 2012, e4248.
20. Hiratsuka S., Goel S., Kamoun W.S., Maru Y., Fukumura D., Duda D.G., Jain R.K. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc. Natl. Acad. Sci. USA 2011, 108:3725-3730.
21. Orr F.W., Wang H.H., Lafrenie R.M., Scherbarth S., Nance D.M. Interactions between cancer cells and the endothelium in metastasis. J. Pathol. 2000, 190:310-329.
22. Geng Y., Marshall J.R., King M.R. Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the circulation. Ann. Biomed. Eng. 2012, 40:790-805.
23. Fiucci G., Ravid D., Reich R., Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002, 21:2365-2375.
24. Jiang C., Wang Z., Ganther H., Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res. 2001, 61:3062-3070.
25. Berezovskaya O., Schimmer A.D., Glinskii A.B., Pinilla C., Hoffman R.M., Reed J.C., Glinsky G.V. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005, 65:2378-2386.
26. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
27. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66:5527-5536.
28. Pedroza-Gonzalez A., Verhoef C., Ijzermans J.N., Peppelenbosch M.P., Kwekkeboom J., Verheij J., Janssen H.L., Sprengers D. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013, 57:183-194.
29. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl. J. Med. 2004, 351:781-791.
30. Bidard F., Fehm T., Ignatiadis M., Smerage J., Alix-Panabieres C., Janni W., Messina C., Paoletti C., Muller V., Hayes D., Piccart M., Pierga J.-Y. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013, 32:179-188.
31. Greene B.T., Hughes A.D., King M.R. Circulating tumor cells: the substrate of personalized medicine?. Front Oncol. 2012, 2:69.
32. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., Yau C., Laird P.W., Ding L., Zhang W., Mills G.B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
33. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New Engl. J. Med. 368 (2013) 2059-2074.
34. Rosing H., Lustig V., van Warmerdam L.J.C., Huizing M.T., ten Vokkel Huinink W.W., Schellens J.H.M., Rodenhuis S., Bult A., Beijnen J.H. Parmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer. Chemother. Pharmacol. 2000, 45:213-218.
35. Barpe D.R., Rosa D.D., Froehlich R.E. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur. J. Pharm. Sci. 2010, 41:458-463.
36. Canal P., Attal M., Chatelut E., Guichard S., Huguet F., Muller C., Schlaifer D., Laurent G., Houin G., Bugat R. Plasma and Cellular Pharmacokinetics of Mitoxantrone in High-Dose Chermotherapeutic Regimen for Refractory Lymphomas. Cancer Res. 1993, 53:4850-4854.